-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on March 23
Revenue exceeds 400 billion
The annual performance is here
Today (March 22), Sinopharm announced its 2020 annual results announcement.
In 2020, Sinopharm realized business income of approximately 456.
4 billion yuan, a year-on-year increase of 7.
32%, and the growth rate was much higher than the industry average.
In 2020, Sinopharm realized business income of approximately 456.
4 billion yuan, a year-on-year increase of 7.
32%, and the growth rate was much higher than the industry average.
The net profit for the whole year was approximately 12.
1 billion yuan, a year-on-year increase of 13.
91%.
The net profit attributable to the parent reached approximately 7.
19 billion yuan, a year-on-year increase of 14.
95%.
1 billion yuan, a year-on-year increase of 13.
91%.
The net profit attributable to the parent reached approximately 7.
19 billion yuan, a year-on-year increase of 14.
95%.
Image source: China Medical Device Official WeChat
Overall, in 2020, the proportion of Sinopharm's pharmaceutical distribution segment revenue decreased by 4.
00 percentage points to 74.
18%, while the medical device and pharmaceutical retail segments increased by 2.
98 percentage points and 0.
56 percentage points, respectively, reaching 19.
04% and 5.
15%.
00 percentage points to 74.
18%, while the medical device and pharmaceutical retail segments increased by 2.
98 percentage points and 0.
56 percentage points, respectively, reaching 19.
04% and 5.
15%.
Among them, in the medical device segment, revenue during the reporting period was approximately 89.
4 billion yuan, accounting for 19.
04% of the total revenue of the Group, an increase of 29.
02% from 2019.
The increase was mainly due to the acquisition and expansion of the medical device business and business growth.
4 billion yuan, accounting for 19.
04% of the total revenue of the Group, an increase of 29.
02% from 2019.
The increase was mainly due to the acquisition and expansion of the medical device business and business growth.
Source: China Medical Device Official Wechat
Previously, Sinopharm Group released the 2020 annual performance data of Sinopharm Equipment.
The annual revenue of Sinopharm Equipment was approximately 58.
36 billion yuan, an increase of 28.
24% year-on-year, and its operating profit was approximately 2.
72 billion yuan, an increase of 73.
5% year-on-year.
The annual revenue of Sinopharm Equipment was approximately 58.
36 billion yuan, an increase of 28.
24% year-on-year, and its operating profit was approximately 2.
72 billion yuan, an increase of 73.
5% year-on-year.
Facing the national centralized procurement, the latest strategy is announced
According to the announcement of Sinopharm Holdings, in 2020, the strict prevention and control measures adopted by hospitals will restrict the development of daily medical operations and hospitalization services, which will have a phased impact on the sales and product structure of the medical device business.
In November 2020, the official landing of high-value consumables with a large amount of procurement marks the official transformation of the device distribution industry into the deep water zone.
The entire device distribution industry is facing a reform path similar to that of drug distribution.
The implementation of the policy will affect the sales revenue of the device sector.
And gross profit margin brings certain pressure, but the advantages of leading companies with network scale advantages and innovative service capabilities are accelerating.
The entire device distribution industry is facing a reform path similar to that of drug distribution.
The implementation of the policy will affect the sales revenue of the device sector.
And gross profit margin brings certain pressure, but the advantages of leading companies with network scale advantages and innovative service capabilities are accelerating.
Facing the new industry situation, Sinopharm Group further enhanced its market coverage.
During the reporting period, the prefecture-level city coverage further increased to 76%.
During the reporting period, the prefecture-level city coverage further increased to 76%.
Sinopharm also stated that in the face of the major changes brought about by the purchase of high-value consumables to the device circulation industry, it will seize the opportunity of increasing the concentration of the existing decentralized market, continue to expand the network layout through endogenous growth and extended mergers and acquisitions, and accelerate the realization of the level.
The above hospitals have effective coverage, while focusing on promoting the linkage of medicine and equipment, and strive to build a national integrated professional service system for medical institutions.
The above hospitals have effective coverage, while focusing on promoting the linkage of medicine and equipment, and strive to build a national integrated professional service system for medical institutions.
At the same time, "device manufacturing" has also become one of the key directions of Sinopharm.
During the reporting period, Sinopharm has initially possessed the production and manufacturing capabilities of more than 100 products in the medical consumable category, and its product sales have covered 31 major cities across the country.
During the reporting period, Sinopharm has initially possessed the production and manufacturing capabilities of more than 100 products in the medical consumable category, and its product sales have covered 31 major cities across the country.
According to the data of Sinopharm’s public conference call, the scale of my country’s device distribution market exceeded 400 billion yuan in 2017.
Promoted by strong terminal market demand, Huatai Securities predicts that the scale of the medical device distribution market will maintain a growth rate of 20% from 2018 to 2020.
It will reach a scale of nearly 700 billion yuan annually.
Promoted by strong terminal market demand, Huatai Securities predicts that the scale of the medical device distribution market will maintain a growth rate of 20% from 2018 to 2020.
It will reach a scale of nearly 700 billion yuan annually.
According to CIC research and analysis, my country’s medical device distribution industry has gradually formed four major operating enterprise clusters in North China Rim Bohai Bay, East China Yangtze River Delta, South China, and Southwest Sichuan.
The number of medical device operating companies in the four major regions accounted for 60% of the country’s total sales account for more than 80% of the country’s total.
The number of medical device operating companies in the four major regions accounted for 60% of the country’s total sales account for more than 80% of the country’s total.
In general, the medical device circulation industry is very sensitive to policies.
The industry is a perfectly competitive industry with a large number of companies and fierce competition among companies.
China's pharmaceutical circulation industry still has the problem of "three lows" as a whole, that is, low concentration, low professional services and low added value/low gross profit margin, low degree of intensification, and the level of development needs to be improved.
The industry is a perfectly competitive industry with a large number of companies and fierce competition among companies.
China's pharmaceutical circulation industry still has the problem of "three lows" as a whole, that is, low concentration, low professional services and low added value/low gross profit margin, low degree of intensification, and the level of development needs to be improved.
Medical Network News on March 23
Revenue exceeds 400 billion
The annual performance is here
Today (March 22), Sinopharm announced its 2020 annual results announcement.
In 2020, Sinopharm realized business income of approximately 456.
4 billion yuan, a year-on-year increase of 7.
32%, and the growth rate was much higher than the industry average.
In 2020, Sinopharm realized business income of approximately 456.
4 billion yuan, a year-on-year increase of 7.
32%, and the growth rate was much higher than the industry average.
The net profit for the whole year was approximately 12.
1 billion yuan, a year-on-year increase of 13.
91%.
The net profit attributable to the parent reached approximately 7.
19 billion yuan, a year-on-year increase of 14.
95%.
1 billion yuan, a year-on-year increase of 13.
91%.
The net profit attributable to the parent reached approximately 7.
19 billion yuan, a year-on-year increase of 14.
95%.
Image source: China Medical Device Official WeChat
Overall, in 2020, the proportion of Sinopharm's pharmaceutical distribution segment revenue decreased by 4.
00 percentage points to 74.
18%, while the medical device and pharmaceutical retail segments increased by 2.
98 percentage points and 0.
56 percentage points, respectively, reaching 19.
04% and 5.
15%.
00 percentage points to 74.
18%, while the medical device and pharmaceutical retail segments increased by 2.
98 percentage points and 0.
56 percentage points, respectively, reaching 19.
04% and 5.
15%.
Among them, in the medical device segment, revenue during the reporting period was approximately 89.
4 billion yuan, accounting for 19.
04% of the total revenue of the Group, an increase of 29.
02% from 2019.
The increase was mainly due to the acquisition and expansion of the medical device business and business growth.
4 billion yuan, accounting for 19.
04% of the total revenue of the Group, an increase of 29.
02% from 2019.
The increase was mainly due to the acquisition and expansion of the medical device business and business growth.
Source: China Medical Device Official Wechat
Previously, Sinopharm Group released the 2020 annual performance data of Sinopharm Equipment.
The annual revenue of Sinopharm Equipment was approximately 58.
36 billion yuan, an increase of 28.
24% year-on-year, and its operating profit was approximately 2.
72 billion yuan, an increase of 73.
5% year-on-year.
The annual revenue of Sinopharm Equipment was approximately 58.
36 billion yuan, an increase of 28.
24% year-on-year, and its operating profit was approximately 2.
72 billion yuan, an increase of 73.
5% year-on-year.
Facing the national centralized procurement, the latest strategy is announced
According to the announcement of Sinopharm Holdings, in 2020, the strict prevention and control measures adopted by hospitals will restrict the development of daily medical operations and hospitalization services, which will have a phased impact on the sales and product structure of the medical device business.
In November 2020, the official landing of high-value consumables with a large amount of procurement marks the official transformation of the device distribution industry into the deep water zone.
The entire device distribution industry is facing a reform path similar to that of drug distribution.
The implementation of the policy will affect the sales revenue of the device sector.
And gross profit margin brings certain pressure, but the advantages of leading companies with network scale advantages and innovative service capabilities are accelerating.
The entire device distribution industry is facing a reform path similar to that of drug distribution.
The implementation of the policy will affect the sales revenue of the device sector.
And gross profit margin brings certain pressure, but the advantages of leading companies with network scale advantages and innovative service capabilities are accelerating.
Facing the new industry situation, Sinopharm Group further enhanced its market coverage.
During the reporting period, the prefecture-level city coverage further increased to 76%.
During the reporting period, the prefecture-level city coverage further increased to 76%.
Sinopharm also stated that in the face of the major changes brought about by the purchase of high-value consumables to the device circulation industry, it will seize the opportunity of increasing the concentration of the existing decentralized market, continue to expand the network layout through endogenous growth and extended mergers and acquisitions, and accelerate the realization of the level.
The above hospitals have effective coverage, while focusing on promoting the linkage of medicine and equipment, and strive to build a national integrated professional service system for medical institutions.
The above hospitals have effective coverage, while focusing on promoting the linkage of medicine and equipment, and strive to build a national integrated professional service system for medical institutions.
At the same time, "device manufacturing" has also become one of the key directions of Sinopharm.
During the reporting period, Sinopharm has initially possessed the production and manufacturing capabilities of more than 100 products in the medical consumable category, and its product sales have covered 31 major cities across the country.
During the reporting period, Sinopharm has initially possessed the production and manufacturing capabilities of more than 100 products in the medical consumable category, and its product sales have covered 31 major cities across the country.
According to the data of Sinopharm’s public conference call, the scale of my country’s device distribution market exceeded 400 billion yuan in 2017.
Promoted by strong terminal market demand, Huatai Securities predicts that the scale of the medical device distribution market will maintain a growth rate of 20% from 2018 to 2020.
It will reach a scale of nearly 700 billion yuan annually.
Promoted by strong terminal market demand, Huatai Securities predicts that the scale of the medical device distribution market will maintain a growth rate of 20% from 2018 to 2020.
It will reach a scale of nearly 700 billion yuan annually.
According to CIC research and analysis, my country’s medical device distribution industry has gradually formed four major operating enterprise clusters in North China Rim Bohai Bay, East China Yangtze River Delta, South China, and Southwest Sichuan.
The number of medical device operating companies in the four major regions accounted for 60% of the country’s total sales account for more than 80% of the country’s total.
The number of medical device operating companies in the four major regions accounted for 60% of the country’s total sales account for more than 80% of the country’s total.
In general, the medical device circulation industry is very sensitive to policies.
The industry is a perfectly competitive industry with a large number of companies and fierce competition among companies.
China's pharmaceutical circulation industry still has the problem of "three lows" as a whole, that is, low concentration, low professional services and low added value/low gross profit margin, low degree of intensification, and the level of development needs to be improved.
The industry is a perfectly competitive industry with a large number of companies and fierce competition among companies.
China's pharmaceutical circulation industry still has the problem of "three lows" as a whole, that is, low concentration, low professional services and low added value/low gross profit margin, low degree of intensification, and the level of development needs to be improved.
Medical Network News on March 23
Revenue exceeds 400 billion
The annual performance is here
The annual performance is here Today (March 22), Sinopharm announced its 2020 annual results announcement.
In 2020, Sinopharm realized business income of approximately 456.
4 billion yuan, a year-on-year increase of 7.
32%, and the growth rate was much higher than the industry average.
In 2020, Sinopharm realized business income of approximately 456.
4 billion yuan, a year-on-year increase of 7.
32%, and the growth rate was much higher than the industry average.
The net profit for the whole year was approximately 12.
1 billion yuan, a year-on-year increase of 13.
91%.
The net profit attributable to the parent reached approximately 7.
19 billion yuan, a year-on-year increase of 14.
95%.
1 billion yuan, a year-on-year increase of 13.
91%.
The net profit attributable to the parent reached approximately 7.
19 billion yuan, a year-on-year increase of 14.
95%.
Image source: China Medical Device Official WeChat
Medical equipment medical equipment Overall, in 2020, the proportion of Sinopharm's pharmaceutical distribution segment revenue decreased by 4.
00 percentage points to 74.
18%, while the medical device and pharmaceutical retail segments increased by 2.
98 percentage points and 0.
56 percentage points, respectively, reaching 19.
04% and 5.
15%.
Medicine, medicine, medicine00 percentage points to 74.
18%, while the medical device and pharmaceutical retail segments increased by 2.
98 percentage points and 0.
56 percentage points, respectively, reaching 19.
04% and 5.
15%.
Among them, in the medical device segment, revenue during the reporting period was approximately 89.
4 billion yuan, accounting for 19.
04% of the total revenue of the Group, an increase of 29.
02% from 2019.
The increase was mainly due to the acquisition and expansion of the medical device business and business growth.
4 billion yuan, accounting for 19.
04% of the total revenue of the Group, an increase of 29.
02% from 2019.
The increase was mainly due to the acquisition and expansion of the medical device business and business growth.
Source: China Medical Device Official Wechat
Previously, Sinopharm Group released the 2020 annual performance data of Sinopharm Equipment.
The annual revenue of Sinopharm Equipment was approximately 58.
36 billion yuan, an increase of 28.
24% year-on-year, and its operating profit was approximately 2.
72 billion yuan, an increase of 73.
5% year-on-year.
The annual revenue of Sinopharm Equipment was approximately 58.
36 billion yuan, an increase of 28.
24% year-on-year, and its operating profit was approximately 2.
72 billion yuan, an increase of 73.
5% year-on-year.
Facing the national centralized procurement, the latest strategy is announced
Facing the national centralized procurement, the latest strategy is announced According to the announcement of Sinopharm Holdings, in 2020, the strict prevention and control measures adopted by hospitals will restrict the development of daily medical operations and hospitalization services, which will have a phased impact on the sales and product structure of the medical device business.
In November 2020, the official landing of high-value consumables with a large amount of procurement marks the official transformation of the device distribution industry into the deep water zone.
The entire device distribution industry is facing a reform path similar to that of drug distribution.
The implementation of the policy will affect the sales revenue of the device sector.
And gross profit margin brings certain pressure, but the advantages of leading companies with network scale advantages and innovative service capabilities are accelerating.
Enterprise business enterpriseThe entire device distribution industry is facing a reform path similar to that of drug distribution.
The implementation of the policy will affect the sales revenue of the device sector.
And gross profit margin brings certain pressure, but the advantages of leading companies with network scale advantages and innovative service capabilities are accelerating.
Facing the new industry situation, Sinopharm Group further enhanced its market coverage.
During the reporting period, the prefecture-level city coverage further increased to 76%.
During the reporting period, the prefecture-level city coverage further increased to 76%.
Sinopharm also stated that in the face of the major changes brought about by the purchase of high-value consumables to the device circulation industry, it will seize the opportunity of increasing the concentration of the existing decentralized market, continue to expand the network layout through endogenous growth and extended mergers and acquisitions, and accelerate the realization of the level.
The above hospitals have effective coverage, while focusing on promoting the linkage of medicine and equipment, and strive to build a national integrated professional service system for medical institutions.
Hospital hospital hospitalThe above hospitals have effective coverage, while focusing on promoting the linkage of medicine and equipment, and strive to build a national integrated professional service system for medical institutions.
At the same time, "device manufacturing" has also become one of the key directions of Sinopharm.
During the reporting period, Sinopharm has initially possessed the production and manufacturing capabilities of more than 100 products in the medical consumable category, and its product sales have covered 31 major cities across the country.
During the reporting period, Sinopharm has initially possessed the production and manufacturing capabilities of more than 100 products in the medical consumable category, and its product sales have covered 31 major cities across the country.
According to the data of Sinopharm’s public conference call, the scale of my country’s device distribution market exceeded 400 billion yuan in 2017.
Promoted by strong terminal market demand, Huatai Securities predicts that the scale of the medical device distribution market will maintain a growth rate of 20% from 2018 to 2020.
It will reach a scale of nearly 700 billion yuan annually.
Promoted by strong terminal market demand, Huatai Securities predicts that the scale of the medical device distribution market will maintain a growth rate of 20% from 2018 to 2020.
It will reach a scale of nearly 700 billion yuan annually.
According to CIC research and analysis, my country’s medical device distribution industry has gradually formed four major operating enterprise clusters in North China Rim Bohai Bay, East China Yangtze River Delta, South China, and Southwest Sichuan.
The number of medical device operating companies in the four major regions accounted for 60% of the country’s total sales account for more than 80% of the country’s total.
The number of medical device operating companies in the four major regions accounted for 60% of the country’s total sales account for more than 80% of the country’s total.
In general, the medical device circulation industry is very sensitive to policies.
The industry is a perfectly competitive industry with a large number of companies and fierce competition among companies.
China's pharmaceutical circulation industry still has the problem of "three lows" as a whole, that is, low concentration, low professional services and low added value/low gross profit margin, low degree of intensification, and the level of development needs to be improved.
Medicine Medicine Medicine The industry is a perfectly competitive industry with a large number of companies and fierce competition among companies.
China's pharmaceutical circulation industry still has the problem of "three lows" as a whole, that is, low concentration, low professional services and low added value/low gross profit margin, low degree of intensification, and the level of development needs to be improved.
